REVIEW ARTICLE
Year : 2013  |  Volume : 6  |  Issue : 2  |  Page : 126-131

Pharmacovigilance in India


Department of Pharmacology, Padmashree. Dr. D.Y. Patil Medical College, Hospital & Research Centre Dr D Y Patil Vidyapeeth, Pimpri, Pune, India

Correspondence Address:
Sarita Mulkalwar
CB-26, Clarion Park, Beside Aundh Tel. Exchange, Aundh, Pune - 411 007
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0975-2870.110288

Rights and Permissions

New drug development is a challenging and costly process as it involves focus on quality, efficacy as well as safety. Some of the adverse drug reactions (ADRs) are predicted based upon the previous experience with the pharmacologically similar drugs and others are detected during clinical trials. For detection of ADRs, clinical trials usually provide limited information as they are conducted under strictly controlled condition and largely focus on efficacy evaluation. Some of the ADRs can be detected only after long-term use in large population and in specific patient groups due to specific concomitant medications or disease. The visual field defect of vigabatrin therapy and valve defect of fenfluramine-phenteramine therapy are few such examples. Therefore early recognition of previously unknown adverse effects of medicines during post-marketing period is the primary objective of pharmacovigilance.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6901    
    Printed174    
    Emailed0    
    PDF Downloaded588    
    Comments [Add]    
    Cited by others 1    

Recommend this journal